✦ LIBER ✦

Final analysis of overall survival in OCEANS, a randomized phase III trial of gemcitabine, carboplatin, and bevacizumab followed by bevacizumab until disease progression in patients with platinum-sensitive recurrent ovarian cancer

✍ Scribed by Aghajanian, C.; Goff, B.A.; Nycum, L.R.; Wang, Y.; Husain, A.; Blank, S.V.

Book ID: 126918741
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 116 KB
Volume: 133
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2014.03.157

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Late-Breaking Abstract 5: Results from a

Late-Breaking Abstract 5: Results from a 2nd interim OS analysis in OCEANS: A randomized phase 3 trial of gemcitabine (G), carboplatin (C) and bevacizumab (BV) followed by BV to disease progression in patients with platinum-sensitive recurrent epithelial ovarian (OC), primary peritoneal (PPC), or fallopian tube cancer (FTC)

✍ C. Aghajanian; S. Blank; B. Goff; P. Judson; L. Nycum; M. Sovak; J. Yi; A. Husai 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 42 KB

OCEANS: A Randomized, Double-Blind, Plac

OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

✍ Aghajanian, C.; Blank, S. V.; Goff, B. A.; Judson, P. L.; Teneriello, M. G.; Hus 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 348 KB

A phase II clinical trial of pegylated l

A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer

✍ Marcela G. del Carmen; John Micha; Laurie Small; Daron G. Street; Anil Londhe; T 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 254 KB

Efficacy in Patient Subgroups in OCEANS,

Efficacy in Patient Subgroups in OCEANS, a Randomized, Double-blinded, Placebo-controlled, Phase 3 Trial of Chemotherapy ± Bevacizumab in Patients with Platinum-sensitive Recurrent Epithelial Ovarian (OC), Primary Peritoneal (PPC), or Fallopian Tube Cancer (FTC)

✍ C. Aghajanian; S.V. Blank; B. Goff; P.L. Judson; S. Makhija; S.K. Sharma; L.R. N 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 50 KB

8029 POSTER Health-Related Quality of Li

8029 POSTER Health-Related Quality of Life (HRQoL)/Patient Reported Outcomes (PRO) of Patients (pts) With Partially Platinum Sensitive (PPS) Recurrent Ovarian Cancer (ROC) Treated in a Randomized Phase III Trial of Trabectedin and Pegylated Liposomal Doxorubicin (PLD) Vs PLD Alone (OVA-301) – an Exploratory Analysis

✍ Verqote, I.; Bidzinski, M.; Kelley, J.; Vasanthan, S.; Runnebaum, I.; Vermorken, 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 45 KB